Merck expects no writedowns for Zetia, Vytorin cholesterol drugs
November 10, 2014 at 15:32 PM EST
Nov 10 (Reuters) - Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs.
